Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables (2016 - 2025)

Historic Receivables for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $114.6 million.

  • Ultragenyx Pharmaceutical's Receivables rose 2054.87% to $114.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year increase of 2054.87%. This contributed to the annual value of $123.6 million for FY2024, which is 6592.97% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Receivables is $114.6 million, which was up 2054.87% from $125.4 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Receivables ranged from a high of $125.4 million in Q2 2025 and a low of $28.5 million during Q2 2021
  • Its 5-year average for Receivables is $70.6 million, with a median of $72.8 million in 2023.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Receivables plummeted by 3495.8% in 2021 and then skyrocketed by 13182.11% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Receivables stood at $44.4 million in 2021, then increased by 5.43% to $46.8 million in 2022, then skyrocketed by 59.01% to $74.5 million in 2023, then skyrocketed by 65.93% to $123.6 million in 2024, then decreased by 7.25% to $114.6 million in 2025.
  • Its Receivables was $114.6 million in Q3 2025, compared to $125.4 million in Q2 2025 and $101.2 million in Q1 2025.